.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Covington
Farmers Insurance
Chinese Patent Office
McKesson
Baxter
Citi
Merck
Cerilliant
Daiichi Sankyo

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 200890

« Back to Dashboard

NDA 200890 describes ISOPTO CARPINE, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from three suppliers. Additional details are available on the ISOPTO CARPINE profile page.

The generic ingredient in ISOPTO CARPINE is pilocarpine hydrochloride. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.

Summary for 200890

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Dental and Oral Agents
Ophthalmic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 200890

Suppliers and Packaging for NDA: 200890

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ISOPTO CARPINE pilocarpine hydrochloride SOLUTION;OPHTHALMIC 200890 NDA Alcon Laboratories, Inc. 0998-0203 0998-0203-15 1 BOTTLE in 1 CARTON (0998-0203-15) > 15 mL in 1 BOTTLE
ISOPTO CARPINE pilocarpine hydrochloride SOLUTION;OPHTHALMIC 200890 NDA Alcon Laboratories, Inc. 0998-0204 0998-0204-15 1 BOTTLE in 1 CARTON (0998-0204-15) > 15 mL in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;OPHTHALMICStrength1%
Approval Date:Jun 22, 2010TE:ATRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;OPHTHALMICStrength2%
Approval Date:Jun 22, 2010TE:ATRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;OPHTHALMICStrength4%
Approval Date:Jun 22, 2010TE:ATRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Accenture
Daiichi Sankyo
Baxter
Colorcon
Fuji
UBS
Harvard Business School
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot